Robert L Coleman

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint 44th Annual Meeting of the American Society of Clinical Oncology
    Robert L Coleman
    Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Gynecol Oncol 110:123-4. 2008
  2. ncbi request reprint Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer
    Aparna A Kamat
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 67:281-8. 2007
  3. ncbi request reprint Rationale for combination use of targeted agents in ovarian cancer: do we have one?
    Robert L Coleman
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:665-7. 2008
  4. ncbi request reprint Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904
    Robert L Coleman
    University of Texas, M D Anderson Cancer Center, Houston, TX, USA Electronic address
    Eur J Cancer 50:1638-48. 2014
  5. pmc Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173
    Robert L Coleman
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 128:155-9. 2013
  6. pmc A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study
    Robert L Coleman
    Dept of Gynecologic Oncology and Reproductive Medicine, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 127:538-43. 2012
  7. pmc Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer
    Duangmani Thanapprapasr
    Department of Gynecologic Oncology, University of Texas, M D Anderson Cancer Center, 1155 Herman Pressler Dr CPB 6 3271, Houston, TX 77030, USA
    Curr Pharm Des 18:2713-9. 2012
  8. ncbi request reprint Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers
    Robert L Coleman
    Department of Gynecologic Oncology, Pathology, and Gynecologic Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 101:126-31. 2006
  9. doi request reprint The Gynecologic Oncology Group's role in the treatment of recurrent cervix cancer: current clinical trials
    Robert L Coleman
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Gynecol Oncol 110:S77-80. 2008
  10. ncbi request reprint Current perspectives on lymphatic mapping in carcinomas of the uterine corpus and cervix
    Robert L Coleman
    Department of Gynecologic Oncology, University of Texas, M D Anderson Cancer Center, 1155 Herman Pressler Drive, CPB 6 3271, Houston, TX 77030, USA
    J Natl Compr Canc Netw 4:471-8. 2006

Collaborators

Detail Information

Publications110 found, 100 shown here

  1. ncbi request reprint 44th Annual Meeting of the American Society of Clinical Oncology
    Robert L Coleman
    Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Gynecol Oncol 110:123-4. 2008
  2. ncbi request reprint Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer
    Aparna A Kamat
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 67:281-8. 2007
    ..05) and led to a decrease in cell-free DNA levels (P < 0.05). Our results suggest that metronomic taxane chemotherapy with dual EGFR and VEGFR inhibition is highly efficacious and should be considered for future clinical trials...
  3. ncbi request reprint Rationale for combination use of targeted agents in ovarian cancer: do we have one?
    Robert L Coleman
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:665-7. 2008
  4. ncbi request reprint Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904
    Robert L Coleman
    University of Texas, M D Anderson Cancer Center, Houston, TX, USA Electronic address
    Eur J Cancer 50:1638-48. 2014
    ..We explored the efficacy, safety and toxicity of docetaxel and vandetanib in women with recurrent ovarian cancer (OC)...
  5. pmc Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173
    Robert L Coleman
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 128:155-9. 2013
    ..To determine which patients with near midline lesions may safely undergo unilateral groin dissection based on clinical exam and lymphoscintigraphy (LSG) results...
  6. pmc A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study
    Robert L Coleman
    Dept of Gynecologic Oncology and Reproductive Medicine, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 127:538-43. 2012
    ..We evaluated activity and toxicity of aflibercept in recurrent/persistent endometrial cancer patients. Biomarkers and association with clinical characteristics and outcome were explored...
  7. pmc Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer
    Duangmani Thanapprapasr
    Department of Gynecologic Oncology, University of Texas, M D Anderson Cancer Center, 1155 Herman Pressler Dr CPB 6 3271, Houston, TX 77030, USA
    Curr Pharm Des 18:2713-9. 2012
    ..Herein, we review the role of these new targets in tumor angiogenesis and the rationale for further clinical development...
  8. ncbi request reprint Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers
    Robert L Coleman
    Department of Gynecologic Oncology, Pathology, and Gynecologic Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 101:126-31. 2006
    ..To evaluate the efficacy and tolerability of imatinib mesylate (Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) in patients with recurrent ovarian and primary peritoneal cancer...
  9. doi request reprint The Gynecologic Oncology Group's role in the treatment of recurrent cervix cancer: current clinical trials
    Robert L Coleman
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Gynecol Oncol 110:S77-80. 2008
    ..While the impact of phase II research queues were presented, the primary focus was to review the pivotal randomized trial which now define practice standards for these women...
  10. ncbi request reprint Current perspectives on lymphatic mapping in carcinomas of the uterine corpus and cervix
    Robert L Coleman
    Department of Gynecologic Oncology, University of Texas, M D Anderson Cancer Center, 1155 Herman Pressler Drive, CPB 6 3271, Houston, TX 77030, USA
    J Natl Compr Canc Netw 4:471-8. 2006
    ..A consensus in corpus cancer has not been reached, although both sites are of keen interest with the increasing use of laparoscopy in surgical management. Prospective multi-institutional validation studies are underway...
  11. pmc A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study
    Robert L Coleman
    Department of Gynecologic Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 122:111-5. 2011
    ..Nab-paclitaxel is a novel Cremophor®-free nanoparticle of albumin-stabilized paclitaxel, which has favorable efficacy and toxicity characteristics relative to other solvent-based taxanes, such as paclitaxel and docetaxel...
  12. ncbi request reprint Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients
    Robert L Coleman
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 12:72-8. 2007
    ..To examine early changes in CA125 relative to objective response in patients with recurrent ovarian cancer treated with pegylated liposomal doxorubicin (PLD) or topotecan and to compare the CA125 trends between the two chemotherapeutics...
  13. ncbi request reprint Historical progress in the initial management of ovarian cancer: intraperitoneal chemotherapy
    Robert L Coleman
    Department of Gynecologic Oncology, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Curr Oncol Rep 8:455-64. 2006
    ..Further evaluation is warranted to clarify unanswered questions regarding administration schedule, agents, techniques, number of courses, and patient eligibility for intraperitoneal chemotherapy...
  14. pmc Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer
    Robert L Coleman
    Department of Gynecologic Oncology and Reproductive Medicine, M D Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 12:1109-17. 2011
    ..We assessed the safety, tolerance, pharmacokinetics, relevant circulating and image-derived biomarkers, and clinical activity of combination aflibercept and docetaxel in this population...
  15. ncbi request reprint 7th annual International Conference on Ovarian Cancer
    Robert L Coleman
    Department of Gynecologic Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 7:119-21. 2007
  16. pmc Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer
    Tae Jin Kim
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer Biol Ther 8:2263-72. 2009
    ..We tested the efficacy of dual targeting of vascular endothelial growth factor (VEGF) and the alpha(V)beta(3) integrin in orthotopic mouse models of ovarian cancer...
  17. pmc Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models
    Chunhua Lu
    Department of Gynecologic Oncology, U T M D Anderson Cancer Center, Houston, TX, USA
    Cancer Biol Ther 9:176-82. 2010
    ..We tested the efficacy of a highly selective aptamer against PDGF-B with or without anti-VEGF therapy in ovarian cancer models...
  18. pmc Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma
    William M Merritt
    Department of Gynecologic Oncology, U T M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Cancer Biol Ther 8:1596-603. 2009
    ..Metronomic chemotherapy regimens have shown anti-tumor activity by anti-angiogenic mechanisms, however, the efficacy of metronomic topotecan in ovarian cancer is not known and the focus of the current study...
  19. pmc EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma
    Jeong Won Lee
    Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:2562-70. 2010
    ..Here, we use an antibody drug conjugate (MEDI-547) composed of a fully human monoclonal antibody against both human and murine EphA2 (1C1) and the tubulin polymerization inhibitor monomethylauristatin F...
  20. pmc Therapeutic Targeting of ATP7B in Ovarian Carcinoma
    Lingegowda S Mangala
    Departments of Gynecologic Oncology, Experimental Therapeutics, and Cancer Biology, The University of Texas M D Anderson Cancer Center, USA
    Clin Cancer Res 15:3770-80. 2009
    ..Here, we examined the biological mechanisms and therapeutic potential of targeting a critical platinum resistance gene, ATP7B, using both in vitro and in vivo models...
  21. pmc Impact of vessel maturation on antiangiogenic therapy in ovarian cancer
    Chunhua Lu
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Obstet Gynecol 198:477.e1-9; discussion 477.e9-10. 2008
    ..The purpose of this study was to examine the functional and therapeutic significance of pericytes in ovarian cancer vasculature...
  22. ncbi request reprint Antitumor and antivascular effects of AVE8062 in ovarian carcinoma
    Tae Jin Kim
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 67:9337-45. 2007
    ..These results suggest that AVE8062 may be useful as a clinical therapeutic approach for ovarian cancer patients and that functional [18F]FDG PET imaging may predict clinical response before an anatomic reduction in tumor size...
  23. pmc Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer
    William M Merritt
    Department of Gynecologic Oncology, Anderson Cancer Center, Houston, TX, USA
    Cancer Biol Ther 10:1306-14. 2010
    ....
  24. ncbi request reprint Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum
    Kathleen M Schmeler
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, 1155 Herman Pressler Drive, Houston, TX 77030, USA
    Gynecol Oncol 108:510-4. 2008
    ..To evaluate the response of women with low-grade serous carcinoma of the ovary or peritoneum to platinum-based neoadjuvant chemotherapy...
  25. doi request reprint Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube
    Ignacio Romero Noguera
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    Gynecol Oncol 125:640-5. 2012
    ..To evaluate the efficacy and tolerability of imatinib mesylate in patients with recurrent low-grade serous carcinoma (LGSC) of the ovary, peritoneum, or fallopian tube...
  26. pmc Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study
    Charles F Levenback
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 440, Houston, TX 77030, USA
    J Clin Oncol 30:3786-91. 2012
    ..To determine the safety of sentinel lymph node biopsy as a replacement for inguinal femoral lymphadenectomy in selected women with vulvar cancer...
  27. pmc Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death
    Alpa M Nick
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Natl Cancer Inst 103:1596-612. 2011
    ..We investigated the clinical and biological significance of p130cas, an important cell signaling molecule, in ovarian carcinoma...
  28. pmc Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma
    Whitney A Spannuth
    Department of Gynecologic Oncology, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77230 1439, USA
    Mol Cancer Ther 9:2377-88. 2010
    ..001), which likely occur through modulation of phosphoinositide 3-kinase signaling. Collectively, these data identify EphB4 as a valuable therapeutic target in ovarian cancer and offer two new strategies for further development...
  29. doi request reprint Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum
    Pedro T Ramirez
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Gynecol Oncol 110:56-9. 2008
    ..To evaluate the efficacy and safety of letrozole in patients with recurrent platinum- and taxane-resistant estrogen receptor-positive (ER+) high-grade cancer of the ovary or peritoneum...
  30. pmc Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer
    William M Merritt
    Departments of Gynecologic Oncology and Cancer Biology, The University of Texas M D Anderson Cancer Center, Unit 1362, PO Box 301439, Houston, TX 77230 1439, USA
    Mol Cancer Ther 9:985-95. 2010
    ..Mol Cancer Ther; 9(4); 985-95. (c)2010 AACR...
  31. pmc EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma
    Jeong Won Lee
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 101:1193-205. 2009
    ....
  32. doi request reprint Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant
    David M Gershenson
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 114:48-52. 2009
    ..The purpose of this study was to further characterize this chemoresistance in recurrent low-grade serous ovarian carcinoma...
  33. pmc Dicer, Drosha, and outcomes in patients with ovarian cancer
    William M Merritt
    University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
    N Engl J Med 359:2641-50. 2008
    ..We studied Dicer and Drosha, components of the RNA-interference machinery, in ovarian cancer...
  34. ncbi request reprint Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary
    David R Crotzer
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 105:404-8. 2007
    ..The purpose of this study was to review our experience with recurrent clear cell carcinoma of the ovary to evaluate its responsiveness to systemic cytotoxic and hormonal agents...
  35. pmc Functional significance of VEGFR-2 on ovarian cancer cells
    Whitney A Spannuth
    Department of Gynecologic Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX, USA
    Int J Cancer 124:1045-53. 2009
    ..001). We show functionally active VEGFR-2 is present on most ovarian cancer cells. The observed anti-tumor activity of VEGF-targeted therapies may be mediated by both anti-angiogenic and direct anti-tumor effects...
  36. doi request reprint Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings
    Pedro T Ramirez
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:1928-34. 2011
    ..No previous studies have prospectively compared positron emission tomography (PET)/computed tomography (CT) with laparoscopic extraperitoneal staging in the evaluation of para-aortic lymph nodes...
  37. pmc Dual targeting of EphA2 and FAK in ovarian carcinoma
    Mian M K Shahzad
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Biol Ther 8:1027-34. 2009
    ..001). These data suggest that the antitumor efficacy of in vivo EphA2 targeting is enhanced in combination with FAK silencing. Dual targeting of EphA2 and FAK may have therapeutic implications for ovarian cancer management...
  38. ncbi request reprint Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial
    Jubilee Brown
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:4973-9. 2010
    ..Because the combination of gemcitabine and cisplatin demonstrated synergism in preclinical studies, the authors attempted to determine the efficacy and toxicity of this combination in women with advanced or recurrent endometrial cancer...
  39. pmc Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth
    Yvonne G Lin
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 14:5437-46. 2008
    ..We sought to determine the effects of inhibiting Aurora kinase on ovarian cancer growth in an orthotopic mouse model using a small molecule pan-Aurora kinase inhibitor, MK-0457...
  40. ncbi request reprint Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma
    Chunhua Lu
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:4209-17. 2007
    ..Pericytes are known to provide a survival advantage for endothelial cells. We hypothesize that strategies aimed at dual targeting of tumor-associated endothelial cells and pericytes will be highly efficacious...
  41. ncbi request reprint Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer
    Charles N Landen
    Department of Gynecologic Oncology, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Biol Ther 5:1708-13. 2006
    ..We sought to determine whether intraperitoneal (IP) delivery of these siRNA complexes was as effective at delivery and therapy as IV delivery...
  42. pmc Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer
    Siqing Fu
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Gynecol Oncol 126:47-53. 2012
    ..On the basis of reversal of taxane resistance with AKT inhibition, we initiated a phase I trial of the AKT inhibitor perifosine with docetaxel in taxane and platinum-resistant or refractory epithelial ovarian cancer...
  43. ncbi request reprint Clinical and biological significance of vascular endothelial growth factor in endometrial cancer
    Aparna A Kamat
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
    Clin Cancer Res 13:7487-95. 2007
    ..Therefore, we examined the clinical and therapeutic significance of VEGF in endometrial carcinoma using patient samples and an endometrioid orthotopic mouse model...
  44. ncbi request reprint Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors
    Xia Tao
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 1439, USA
    Gynecol Oncol 114:431-6. 2009
    ..Ovarian granulosa cell tumors tend to respond poorly to chemotherapy. We examined the clinical efficacy of bevacizumab with or without concurrent chemotherapy and evaluated the angiogenic characteristics of these patients' tumors...
  45. ncbi request reprint Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model
    Jenifer M Saucier
    Department of Gynecologic Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Oncol Pharm Pract 13:39-45. 2007
    ....
  46. pmc Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer
    Siqing Fu
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:1661-9. 2011
    ..A phase 1b-2a clinical trial of this sequential combination of azacitidine and carboplatin was initiated in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer...
  47. pmc Targeting SRC and tubulin in mucinous ovarian carcinoma
    Tao Liu
    Authors Affiliations Departments of Gynecologic Oncology and Reproductive Medicine, Genitourinary Medical Oncology, Bioinformatics and Computational Biology, and Cancer Biology Division of Cancer Medicine Center for RNA Interference and Non Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas Kinex Pharmaceuticals LLC, New York State Center of Excellence in Bioinformatics and Life Sciences, Buffalo, New York Department of General Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Department of Gynecology, Obstetrics and Gynecology, Hospital of Fudan University, Shanghai, P R China
    Clin Cancer Res 19:6532-43. 2013
    ..To investigate the antitumor effects of targeting Src and tubulin in mucinous ovarian carcinoma...
  48. pmc Regulation of tumor angiogenesis by EZH2
    Chunhua Lu
    Department of Gynecologic Oncology, U T M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 18:185-97. 2010
    ..Collectively, these data support the potential for targeting ezh2 as an important therapeutic approach...
  49. pmc Clinical and biological significance of tissue transglutaminase in ovarian carcinoma
    Jee Young Hwang
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 68:5849-58. 2008
    ..Taken together, these findings indicate that TG2 overexpression is an adverse prognostic factor in ovarian carcinoma and TG2 targeting may be an attractive therapeutic approach...
  50. doi request reprint Primary peritoneal serous carcinoma presenting as inflammatory breast cancer
    Ibrahim Khalifeh
    Department of Pathology, MD Anderson Cancer Center, Houston, Texas, USA
    Breast J 15:176-81. 2009
    ..To our knowledge, this is the first reported case of an extramammary primary malignancy that not only presented as inflammatory breast cancer but also was diagnosed and initially treated as such...
  51. pmc EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer
    Aparna A Kamat
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Cancer 115:2684-92. 2009
    ..The objective of the current investigation was to study the role of EphA2 in endometrial cancer and its relation to steroid hormone receptor expression...
  52. doi request reprint Rate of para-aortic lymph node micrometastasis in patients with locally advanced cervical cancer
    Behrouz Zand
    Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX 77030, USA
    Gynecol Oncol 119:422-5. 2010
    ..To determine the rate of para-aortic node micrometastasis in patients with locally advanced cervical cancer undergoing laparoscopic extraperitoneal para-aortic lymphadenectomy...
  53. doi request reprint Lymphatic mapping and sentinel lymph node detection in women with vaginal cancer
    Michael Frumovitz
    Department of Gynecologic Oncology, CPB6 3244, Unit 1362, The University of Texas M D Anderson Cancer Center, 1155 Herman Pressler, Houston, TX 77030, USA
    Gynecol Oncol 108:478-81. 2008
    ..To determine the patterns of lymphatic drainage from primary vaginal cancers utilizing lymphoscintigraphy and to determine if this clinical information would affect treatment planning...
  54. pmc Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma
    Liz Y Han
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 66:8633-9. 2006
    ..Thus, Src inhibition may be an attractive therapeutic approach for patients with ovarian carcinoma...
  55. pmc Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer
    Cristina Ivan
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Gynecol Oncol 128:506-11. 2013
    ..We used The Cancer Genome Atlas (TCGA) data to study the clinical relevance of epigenetic modifications of Notch superfamily genes...
  56. pmc Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer
    Wei Hu
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 71:6030-9. 2011
    ....
  57. ncbi request reprint Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer
    Michael Frumovitz
    Department of Gynecologic Oncology, CPB6 3244, Unit 1362, The University of Texas M D Anderson Cancer Center, 1155 Herman Pressler, TX 77030, USA
    Gynecol Oncol 104:100-3. 2007
    ..To evaluate fundal injection of blue dye and radiocolloid for lymphatic mapping and sentinel node identification in women with high-risk endometrial cancer...
  58. ncbi request reprint Usefulness of preoperative lymphoscintigraphy in patients who undergo radical hysterectomy and pelvic lymphadenectomy for cervical cancer
    Michael Frumovitz
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Obstet Gynecol 194:1186-93; discussion 1193-5. 2006
    ..The purpose of this study was to assess the value of preoperative lymphoscintigraphy before intraoperative lymphatic mapping for sentinel lymph node identification during radical hysterectomy...
  59. pmc Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary
    Satoshi Takeuchi
    Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA Electronic address
    Gynecol Oncol 133:100-4. 2014
    ..The utility of 18F-FDG PET/CT in monitoring patients with LGSC has not been established. We assessed the accuracy and clinical impact of 18F-FDG PET/CT in patients with ovarian LGSC after initial treatment...
  60. doi request reprint Risk of thromboembolic disease in patients undergoing laparoscopic gynecologic surgery
    Alpa M Nick
    Department of Gynecologic Oncology, The University of Texas MD Anderson Medical Cancer Center, Houston, Texas 77030, USA
    Obstet Gynecol 116:956-61. 2010
    ..To estimate the incidence of venous thromboembolism among patients undergoing gynecologic laparoscopy and characterize the risk of venous thromboembolism among patients with gynecologic malignancy...
  61. doi request reprint A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma
    Robin A Lacour
    Department of Gynecologic Oncology, Louisiana State University Health Science Center at Shreveport, LA, USA
    Int J Gynecol Cancer 21:517-22. 2011
    ..The most widely studied regimen is ifosfamide and cisplatinum. Moderate success has been documented using paclitaxel in ovarian CS. The purpose of this study was to evaluate carboplatin/paclitaxel in advanced and recurrent uterine CS...
  62. ncbi request reprint Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer
    Pedro T Ramirez
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    Gynecol Oncol 108:68-71. 2008
    ....
  63. pmc Evaluation of pegylated liposomal doxorubicin dose on the adverse drug event profile and outcomes in treatment of recurrent endometrial cancer
    Justin M Julius
    Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Int J Gynecol Cancer 23:348-54. 2013
    ....
  64. doi request reprint Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study
    Diane C Bodurka
    The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:3087-94. 2012
    ....
  65. ncbi request reprint Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma
    Chunhua Lu
    Departments of Gynecologic Oncology and Cancer Biology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 67:1757-68. 2007
    ..The present study shows that tumor and normal endothelium differ at the molecular level, which may have significant implications for the development of antiangiogenic therapies...
  66. doi request reprint A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma
    Brian M Slomovitz
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 116:5415-9. 2010
    ..Loss of PTEN or activation of PIK3CA results in constitutive activation of AKT, which leads to up-regulation of mammalian target of rapamycin (mTOR). Everolimus is an oral rapamycin analog that acts by selectively inhibiting mTOR...
  67. ncbi request reprint Selected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004
    Anil K Sood
    Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    Expert Opin Pharmacother 6:1269-75. 2005
  68. doi request reprint Conservative surgery in early-stage cervical cancer: what percentage of patients may be eligible for conization and lymphadenectomy?
    Ashlee L Smith
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 119:183-6. 2010
    ....
  69. doi request reprint Angiogenesis as a strategic target for ovarian cancer therapy
    Whitney A Spannuth
    Departments of Gynecologic Oncology and Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Nat Clin Pract Oncol 5:194-204. 2008
    ..This Review highlights the results of the latest clinical studies of antivascular agents in ovarian cancer and discusses the challenges and opportunities for future clinical trials...
  70. pmc A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies
    John W Moroney
    Department of Gynecology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 17:6840-6. 2011
    ..We, therefore, added temsirolimus (T), which inhibits HIF-1╬▒, to D and A (DAT). Trial objectives were assessment of safety, preliminary efficacy, and identification of biological response correlates...
  71. pmc Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer
    Rebecca L Stone
    Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    Lancet Oncol 11:465-75. 2010
    ..This review discusses the leading toxic effects encountered and anticipated in clinical investigation and practice with antiangiogenic agents in patients with ovarian cancer, with particular focus on potential management strategies...
  72. pmc Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker
    Aparna A Kamat
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230, USA
    Cancer 116:1918-25. 2010
    ..The authors sought to determine the role of preoperative total plasma cell-free DNA levels in predicting clinical outcome in patients with ovarian cancer...
  73. ncbi request reprint Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary
    David M Gershenson
    Department of Gynecologic Oncology and Pathology, The University of Texas M D Anderson Cancer Center, Houston, 77230 1439, USA
    Obstet Gynecol 108:361-8. 2006
    ..To analyze the clinical behavior of patients with stage II-IV low-grade serous carcinoma of the ovary seen at our institution who underwent primary surgery followed by platinum-based chemotherapy...
  74. pmc Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy
    Jyotsnabaran Halder
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 12:4916-24. 2006
    ..Based on encouraging in vitro results with FAK silencing, we examined the in vivo therapeutic potential of this approach using short interfering RNA (siRNA) in the neutral liposome 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC)...
  75. ncbi request reprint Total laparoscopic radical hysterectomy and lymphadenectomy: the M. D. Anderson Cancer Center experience
    Pedro T Ramirez
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Unit 1362, Houston, TX 77230 1439, USA
    Gynecol Oncol 102:252-5. 2006
    ..To retrospectively evaluate the feasibility and morbidity of total laparoscopic radical hysterectomy and lymphadenectomy...
  76. ncbi request reprint Role of appendectomy at the time of primary surgery in patients with early-stage ovarian cancer
    Pedro T Ramirez
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Unit 1362, Houston, TX 77230 1439, USA
    Gynecol Oncol 103:888-90. 2006
    ..To determine whether appendectomy is warranted in patients with apparent early-stage ovarian cancer who undergo surgery for staging and cytoreduction and to determine the complication rate associated with appendectomy in such patients...
  77. ncbi request reprint Lymphatic mapping and sentinel node identification in patients with cervix cancer undergoing radical hysterectomy and pelvic lymphadenectomy
    Charles Levenback
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 20:688-93. 2002
    ....
  78. doi request reprint Farletuzumab in epithelial ovarian carcinoma
    Whitney A Spannuth
    University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology, 1155 Herman Pressler Drive, Houston, TX 77030 3271, USA
    Expert Opin Biol Ther 10:431-7. 2010
    ..Farletuzumab (MORAb-003) is a humanized mAb with high affinity for folate receptor alpha (FRalpha), a 38 kDa GPI-anchored protein that is overexpressed in 90% of epithelial ovarian cancers...
  79. ncbi request reprint Ovarian cancer
    Bryan T Hennessy
    Department of Gynecologic Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet 374:1371-82. 2009
    ....
  80. pmc Aflibercept in epithelial ovarian carcinoma
    John W Moroney
    Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030 3721, USA
    Future Oncol 5:591-600. 2009
    ..Finally, the anticipated role of aflibercept in the treatment of epithelial ovarian carcinoma is also discussed...
  81. ncbi request reprint Supracervical hysterectomy in patients with advanced epithelial ovarian cancer
    Michael R Milam
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Obstet Gynecol 109:641-6. 2007
    ..To assess whether supracervical hysterectomy (SCH) is a reasonable alternative to total abdominal hysterectomy in patients with advanced ovarian cancer...
  82. ncbi request reprint Primary neuroendocrine carcinoma of the vagina with Merkel cell carcinoma phenotype
    Neil M Coleman
    Department of Pathology, Baylor College of Medicine, Houston, TX 77030, USA
    Am J Surg Pathol 30:405-10. 2006
    ..Positive expression of CK20 in primary small cell carcinoma of the vagina might represent a Merkel cell carcinoma subtype of this tumor...
  83. ncbi request reprint Tumor board: more than treatment planning--a 1-year prospective survey
    Troy A Gatcliffe
    Department of Obstetrics and Gynecology, University of Texas, Southwestern Medical Center, Dallas, TX, USA
    J Cancer Educ 23:235-7. 2008
    ..The aim of this study was to evaluate the impact of gynecologic oncology tumor boards (TBs) on patient care and graduate education...
  84. ncbi request reprint Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma
    Premal H Thaker
    Department of Gynecologic Oncology, University of Texas U T M D Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, Texas 77030, USA
    Nat Med 12:939-44. 2006
    ..These data also suggest that blocking ADRB-mediated angiogenesis could have therapeutic implications for the management of ovarian cancer...
  85. ncbi request reprint Effects of a laboratory-based skills curriculum on laparoscopic proficiency: a randomized trial
    Robert L Coleman
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Texas, Southwestern Medical Center, Dallas, USA
    Am J Obstet Gynecol 186:836-42. 2002
    ..The purpose of this study was to determine the effect and validity of an intensive laboratory-based laparoscopic skills training curriculum on operative proficiency in obstetrics and gynecology residents...
  86. ncbi request reprint Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis
    Ricardo dos Reis
    Hospital de Clinicas de Porto Alegre, Gynecologic Oncology Service, Universidade Federal do Rio Grande do Sul, Ramiro Barcelos 2350, Porto Alegre, Brazil
    Gynecol Oncol 107:458-63. 2007
    ..To evaluate whether histology (adenocarcinoma versus adenosquamous carcinoma) is an independent prognostic indicator in patients with stage IB1 cervical cancer after radical hysterectomy...
  87. ncbi request reprint CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan
    Gabrielle Gossner
    Washington University School of Medicine, St Louis, MO 63110, USA
    Gynecol Oncol 103:212-8. 2006
    ..In this study, we sought to gain insight into response patterns regarding CA-125 in responders vs. non-responders and to determine whether specific "cut-off" values could help predict ultimate clinical response...
  88. ncbi request reprint Emerging role of topotecan in front-line treatment of carcinoma of the ovary
    Robert L Coleman
    Obstetrics and Gynecology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Building J7 124, Dallas, TX 75390 9032, USA
    Oncologist 7:46-55. 2002
    ..This review summarizes the preliminary clinical findings associated with the four strategies and outlines ongoing and future randomized studies of topotecan in front-line ovarian cancer...
  89. ncbi request reprint The use of adjuvant radiation therapy in early endometrial cancer by members of the Society of Gynecologic Oncologists in 2005
    R Wendel Naumann
    Department of Ob Gyn, Carolinas Medical Center, Charlotte, NC 28232, USA
    Gynecol Oncol 105:7-12. 2007
    ..To determine current patterns of care for early stage endometrial cancer by the members of the Society of Gynecologic Oncologists (SGO)...
  90. ncbi request reprint Surgical staging of ovarian low malignant potential tumors
    Gautam G Rao
    Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Obstet Gynecol 104:261-6. 2004
    ..The purpose of this study was to compare the outcome of surgically staged patients with low malignant potential tumors with those who were not staged...
  91. ncbi request reprint The role of maintenance therapy and novel taxanes in ovarian cancer
    Thomas J Herzog
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University, Herbert Irving Cancer Center, 161 Ft Washington Avenue, New York, NY 10032, USA
    Gynecol Oncol 102:218-25. 2006
    ..In addition, the role of novel taxanes, which may offer an improved therapeutic index and reduced toxicity relative to conventional therapies in this setting, is discussed...
  92. ncbi request reprint Cervical adenocarcinoma survival among Hispanic and white women: a multicenter cohort study
    John O Schorge
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas 75390, USA
    Am J Obstet Gynecol 188:640-4. 2003
    ..We compared the clinical outcome of cervical adenocarcinoma in Hispanic and white women to determine whether race was an independent predictor of survival...
  93. ncbi request reprint Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer
    Keiichi Fujiwara
    Department of Obstetrics and Gynecology, Kawasaki Medical School, 577 Matsushima, Kurashiki City 701 0192, Japan
    Gynecol Oncol 97:10-5. 2005
    ..In this review article, we discuss the current status and future perspectives of IP chemotherapy for ovarian cancer...
  94. ncbi request reprint Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer
    Gautam G Rao
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Gynecol Oncol 96:168-72. 2005
    ..This study was done to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of weekly paclitaxel/carboplatin chemoradiotherapy in locally advanced cervix cancer...
  95. ncbi request reprint Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer
    Snehal M Bhoola
    Division of Gynecologic Obstetrics, University of Alabama at Birmingham, Birmingham, AL 35249, USA
    Gynecol Oncol 95:564-9. 2004
    ..To retrospectively investigate the safety and efficacy of weekly topotecan in heavily pretreated patients with ovarian cancer...
  96. ncbi request reprint Other primary malignancies in patients with uterine corpus malignancy
    Jacquelyn B Delin
    Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9032, USA
    Am J Obstet Gynecol 190:1429-31. 2004
    ..The purpose of this study was to determine the occurrence of multiple primary malignancies in patients with uterine corpus malignancy...
  97. ncbi request reprint Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma
    Jayanthi S Lea
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9032, USA
    Gynecol Oncol 91:558-62. 2003
    ..The purpose of this study was to identify poor prognostic factors of low-risk stage IB1 cervical adenocarcinoma..
  98. ncbi request reprint A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy
    Thomas J Herzog
    Columbia University, New York, NY 10032, USA
    Am J Obstet Gynecol 195:445-53. 2006
    ..The purpose of this study was to investigate the safety and efficacy of alvimopan, a novel peripherally acting mu-opioid receptor antagonist, in patients who undergo simple total abdominal hysterectomy...
  99. ncbi request reprint Primary vaginal melanoma: a rare and problematic clinical entity
    Robert L Coleman
    Ann Surg Oncol 11:4-6. 2004
  100. ncbi request reprint Analysis of prognostic factors for patients with leiomyoma treated with uterine arterial embolization
    Seiji Isonishi
    Department of Obstetrics and Gynecology, Jikei University School of Medicine, Aoto Hospital, Tokyo, Japan
    Am J Obstet Gynecol 198:270.e1-6. 2008
    ..The objective of the study was to describe a clinically useful factors index predicting long-term efficacy of uterine artery embolization (UAE)...
  101. ncbi request reprint Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies
    Richard D Drake
    Department of Ob Gyn, Division of Gynecologic Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 9032, USA
    Gynecol Oncol 94:320-4. 2004
    ..The aim of this study is to evaluate the effect of oral dexamethasone in attenuating palmar-plantar erythrodysesthesias (PPE) in Doxil-treated patients for gynecologic malignancies...